Monopar Therapeutics cotiza a 77.05 USD y tiene una capitalización bursátil de $517M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.62 | $-0.46 | $-0.61 |
| Estimado | $-0.85 | $-0.65 | $-0.90 | $-0.51 |
| Sorpresa | — | +4.6% | +48.9% | -19.6% |
| Métrica | MNPR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -9.9% | -40.4% | +30.4% |
| ROA | -9.8% | -32.0% | +22.3% |
| Current Ratio | 51.35 | 2.84 | +48.51 |
| Debt / Equity | — | 0.28 | — |